Jasim Uddin
☆    

Bangladesh,
2018-06-20 15:29
(2925 d 11:20 ago)

Posting: # 18929
Views: 4,269
 

 Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

Post reply
Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards

Jasim

Edit: Category changed; see also this post #1. [Helmut]
 
Jasim Uddin
☆    

Bangladesh,
2018-06-24 12:28
(2921 d 14:21 ago)

@ Jasim Uddin
Posting: # 18955
Views: 3,202
 

 Bio-equivalence of IR Tablet against ER Tablet

Post reply
Hi Sir Helmut

Can you please help me out in the following issue?

Regards

Jasim

Edit: Relax; see also this post #9. Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
147 visitors (0 registered, 147 guests [including 31 identified bots]).
Forum time: 02:49 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5